Skip to main content
. 2022 May 26;127(4):747–756. doi: 10.1038/s41416-022-01821-7

Fig. 3. Oncogenic pathway and therapeutic actionability analyses in the broad-panel NGS cohort.

Fig. 3

a Oncoprint of altered oncogenic pathways by radiological subtype. Pathway alterations were presented by increasing NPA. b Comparison of alteration frequency of oncogenic pathways among radiological subtypes. Pathways with significant differences using Fisher’s exact test were labelled with asterisks (FDR q < 0.100), while those with significant differences in Cochran–Armitage test for trend are highlighted in red (P < 0.050). c Frequency of NPA versus radiological subtype. d Frequency of samples with actionable alteration by radiological subtype. e Level of evidence versus radiological subtype. Samples were classified by the alteration that carried the highest level of evidence. f Frequency of the number of actionable alteration versus radiological subtype. FDR false discovery rate, NPA number of pathway alteration.